JP Stock MarketDetailed Quotes

4552 JCR Pharmaceuticals

Watchlist
  • 607
  • -2-0.33%
20min DelayMarket Closed Dec 30 15:30 JST
78.72BMarket Cap13.82P/E (Static)

JCR Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

JCR Pharmaceuticals Q2 2025 Earnings Date

Currency：JPYOct 30, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
11.30B
8.51B
-2.79B
Miss Est.
-16.07%
-36.78%
-24.67%
EPS
15.27
-7.14
-22.41
Miss Est.
-47.68%
-124.57%
-146.74%
Analyst Rating
Buy

Dec 18, 2024

JCR Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 16.043B--
Jan 31, 20252025/Q3-- / 11.300B--
Oct 30, 20242025/Q28.512B / 11.300B--
Jul 30, 20242025/Q18.145B / 11.300B--
May 10, 20242024/Q49.153B / 12.382B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 16.043B--
Jan 31, 20252025/Q3-- / 11.300B--
Oct 30, 20242025/Q28.512B / 11.300B--
Jul 30, 20242025/Q18.145B / 11.300B--
May 10, 20242024/Q49.153B / 12.382B--

Unlock Free Earnings Estimates

JCR Pharmaceuticals Earnings Reports

  • JCR Pharmaceuticals: Confirmation letter

    Nov 14 10:16

  • JCR Pharmaceuticals: Half Year Report - Term 50 (2024/04/01 - 2025/03/31)

    Nov 14 10:15

  • JCR Pharmaceuticals: Financial results briefing materials for the 2nd quarter of the fiscal year ending March 31, 2025

    Oct 30 15:00

  • JCR Pharmaceuticals: Notice Concerning Dividends from Surplus Funds (Interim Dividend)

    Oct 30 15:00

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 18, 2024

    Buy

    • Strong Buy

      28.57%

    • Buy

      0.00%

    • Hold

      71.43%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Price
    % Chg

    No Data